LimmaTech Biologics
A Swiss clinical-stage biotech company applying its knowledge of engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases.
Spun out from GlycoVaxyn after that company’s acquisition by GSK, LimmaTech Bio is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance and sexually transmitted infections such as gonorrhea, alongside partnered programs with GSK.
Latest LimmaTech Biologics News & Features
20 December 2023
9 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze